维升药业－Ｂ(02561.HK)公布招股结果，香港公开发售接获72.64倍认购，一手(100股)中签率6.27%，认购2,000股获稳派一手。按回补机制，公开发售股份增至455.4万股，占发售总数40%。国际发售录得1.65倍认购。最终发售价68.8元，近下限定价，集资净额6.72亿元。股份预期周五(21日)挂牌。(de/d)(港股报价延迟最少十五分钟。)
维升药业－Ｂ(02561.HK)公布招股结果，香港公开发售接获72.64倍认购，一手(100股)中签率6.27%，认购2,000股获稳派一手。按回补机制，公开发售股份增至455.4万股，占发售总数40%。国际发售录得1.65倍认购。最终发售价68.8元，近下限定价，集资净额6.72亿元。股份预期周五(21日)挂牌。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.